1. Reducing Risk for CV Outcomes

2. Program Goals

3. GLAGOV Evolocumab vs Placebo in Statin-Treated Patients

4. GLAGOV Impact of PCSK9i on Coronary Disease Progression

5. Effects of Lipid Lowering by PCSK9 mAbs on Inflammation in FH

6. Potential Benefits of Very Low LDL-C Levels

7. FOURIER Evolocumab vs Placebo in Statin-Treated Patients

8. FOURIER Primary and Secondary Efficacy Endpoints

9. FOURIER Key Subgroups

10. FOURIER Safety

11. Clinical Implications of FOURIER

12. SPIRE Trials Bococizumab vs Placebo in High-Risk Patients

13. SPIRE-1 and SPIRE-2 Confirmation of Attenuation in LDL-C Reduction Over Time

14. SPIRE Bococizumab CV Outcomes

15. Access to Nonstatin LLTs for High-Risk Patients

16. Algorithm: Treatment of HeFH and Clinical ASCVD With PCSK9 Inhibitors

17. Improving Access to PCSK9 Inhibitors

18. Summary

19. Abbreviations

20. Abbreviations (cont)

21. Abbreviations (cont)